221 results about "Morphogenesis" patented technology

The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.

Methods and devices are described for the regulation of bone morphogenetic protein gene expression in bone cells via the application of fields generated by specific and selective electric and electromagnetic signals in the treatment of diseased or injured bone. By gene expression is meant the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased bone tissue that include generating specific and selective electric and electromagnetic signals that generate fields optimized for increase of bone morphogenetic protein gene expression and exposing bone to the fields generated by specific and selective signals so as to regulate bone morphogenetic protein gene expression in such bone tissue. The resulting methods and devices are useful for the targeted treatment of bone fractures, fractures at risk, delayed unions, nonunion of fractures, bone defects, spine fusions, osteonecrosis or avascular necrosis, as an adjunct to other therapies in the treatment of one or all of the above, and in the treatment of osteoporosis.

Methods and compositions are provided for the treatment of articular cartilage defects and disease involving the combination of tissue, such as osteochondral grafts, with active growth factor. The active growth factor is preferably a composition containing at least one bone morphogenetic protein and a suitable carrier. The method results in the regeneration and / or functional repair of articular cartilage tissue.

Disclosed are methods and compositions for maintaining neural pathways in a mammal including: enhancing survival of neurons at risk of dying; inducing cellular repair of damaged neurons and neural pathways; stimulating neurons to maintain their differentiated phenotype; and promoting dendritic outgrowth, including maintaining dendritic arbors and regenerating dendritic architecture. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration. In another embodiment, the invention provides methods and compositions which include a morphogen or morphogen-stimulating agent, and a nerve trophic factor or nerve trophic factor-stimulating agent at concentrations effective for stimulating dendrite outgrowth. The morphogen and the nerve trophic factor can be admixed in combination.

Bone morphogenetic proteins (BMPs) are introduced into an affected intervertebral disc without the inclusion of disc cells. The inventions applies to all known and yet-to-be developed or discovered BMPs, including BMP-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, . . . BMPn. The BMP(s) may be obtained from natural and / or recombinant sources. The BMP(s) may be introduced using any surgical technique, including percutaneous or laparoscopic approaches. As one delivery mechanism, a passageway may be formed through the annulus, with the substances then being introduced through the passageway. Alternatively, a carrier may be sewn or otherwise adhered to the inside or outside of the existing annulus using standard surgical procedures. Additional therapeutic substances such as culture medium, growth factors, differentiation factors, hydrogels, polymers, antibiotics, anti-inflammatory medications, or immunosuppressive medications could be introduced in conjunction with the BMP(s).

A method has been developed to produce stable cell-matrix microspheres with up to 100% encapsulation efficiency and high cell viability, using matrix or biomaterial systems with poor shape and mechanical stability for applications including cell therapeutics via microinjection or surgical implantation, 3D culture for in vitro expansion without repeated cell splitting using enzymatic digestion or mechanical dissociation and for enhanced production of therapeutic biomolecules, and in vitro modeling for morphogenesis studies. The modified droplet generation method is simple and scalable and enables the production of cell-matrix microspheres when the matrix or biomaterial system used has low concentration, with slow phase transition, with poor shape and mechanical stability.

The invention provides pharmaceutical compositions for the treatment of neuroinflammatory or neurodegenerative diseases comprising a single or a combination of several blocking agent(s) of Bone Morphogenic Protein (BMP) signaling. The invention further provides methods of treatment of neuroinflammatory or neurodegenerative diseases comprising administering to a patient in need thereof the pharmaceutical compositions of the invention.

The present invention provides a tissue culture method for cultivation of marine algae, said method comprising the steps of (i) establishing axenic viable algal material by sequential treatment thereof in sterile sea water supplemented with domestic liquid detergent, incubating the treated material, (ii) culturing the axenic explants on agarified medium for induction of callus; (iii) excising and subculturing the calli from the axenic explants on fresh agar plates to obtain differentiated densely pigmented oval or spherical shaped micro-propagules (iv) subculturing the pigmented calli in agarified medium to achieve enhanced somatic embryogenesis and micro-propagule formation in pigmented filamentous callus, (v) transferring the filamentous calli with somatic embryos for morphogenesis and development of young plantlets; and (vi) cultivating algal biomass on a large scale by growing the young plantlets in enclosed perforated polythene bags.

The invention relates to a cell model obtained after targeted knockout of a rabbit BMP2 gene based on CRISPR / Cas9 and application thereof, belonging to the technical field of molecular biology and biomedicine. According to the invention corresponding oligos are synthesized for three targeting sites of the rabbit BMP2 gene on the design principles of CRISPR / Cas9 and are constructed on px458 vectors; and a CRISPR / Cas9 system is constructed directed at the three targeting sites in rabbit mesenchymal stem cells, and the CRISPR / Cas9 system can effectively knock out the rabbit BMP2 gene, is easy to operate and has high rabbit BMP2 gene knockout efficiency. The cell model disclosed in the invention can greatly promote research related to the functions and signaling pathways of the BMP2 gene.

The invention belongs to the fields of development and utilization of plant growth regulating substances, and discloses a hydrogen-rich liquid plant growth regulator. The saturation of hydrogen in a solvent is 0.1 to 100 percent, and the solvent is water, a 25 to 100 percent Hoagland nutrient solution, a Kimura B nutrient solution, a TAP nutrient solution or an MS culture solution. Calcium salt, salicylic acid, salicylate, salicylic acid derivative, humid acid or humic acid salt at the final concentration of 0-1,000mu mol / L is added into the solvent. Plants, plant tissues and seeds are irrigated, sprayed or soaked, the plant growth and morphogenesis can be effectively promoted, seed germination is quickened, heavy metal accumulation is reduced, and the oxidation resistance and stress resistance / tolerance are improved. The method has the characteristics of no pollution, environmental protection, low cost, and wide application range, and is applied to the fields such as farmland chemical regulation, provenance agriculture, environment and plant nutrition, plant tissue culture and cut flower preservation time prolonging.

The present invention pertains to the use of BMP-2, which is overexpressed in most common cancers, as 1) a target for cancer treatment therapies and 2) a means to diagnose cancer. The therapeutic component of this invention involves administering to a patient a composition that inhibits bone morphogenetic-2 activity. Such inhibition may be accomplished by ligands or antibodies that bind to BMP-2 or BMP-2 receptors. It may also be achieved by preventing the processing of pro-BMP-2, or blocking transcription or replication of BMP-2 DNA or translation of BMP-2 mRNA. The diagnostic component of the invention involves measuring the BMP-2 level in biological samples from both a patient and a subject and comparing those levels. Elevated levels of BMP-2 in the patient compared to the non-cancerous subject indicate cancer.

The invention discloses a long-chain recombination human bone pattern generating protein-2 and preparing method and application, which is characterized by the following: utilizing gene project technique to grow the protein in the expressing system of escherichia coli and bacillus subtilis; adopting human bone sarcoma cell mRNA to do reverse transcription to obtain the cDNA as form; augmenting nucleotide sequence of entire 114 amino acids naturally from carboxyl end; adding a segment of nucleotide in front of the first codon of primer 5' end; increasing a segment of polypeptide at N end corresponding to amino acid sequence; obtaining long-chain rhBMP-2 gene with molecular weight at 30KD and purity over 95%.

The present invention provides methods of repairing and regenerating cartilage tissue using a soluble morphogenic protein complex comprising (a) a morphogenic protein; and (b) a morphogenic protein pro region isolated from a morphogenic protein, or a conservative substitution variant or a fragment of said pro region, wherein said pro region or variant or fragment is noncovalently linked to the morphogenic protein, and wherein said complex is more soluble in an aqueous solvent than said morphogenic protein alone.

Of the bioactive gel injection material for bone repairing, each dose consists of component A in 1 ml and component B in 45-55 mg. The component A contains sodium alginate 10-40 mg, bone morphogenetic protein 0.1-1 mg and mannitol 10-20 mg in each ml of bacteria-free physiological saline. Of the component B, each mg contains water insoluble calcium compound 0.05-0.15 mg, gluconolactone 0.05-0.3 mg and polyvinyl pyrrolidone 0.004-0.016 mg except mannitol. The injection material for bone repairing has excellent biocompatibility and simple and safe use, and may be injected to required bone treating position. Animal experiment shows that it has similar bone forming activity to operation implanted solid bone repairing material containing bone morphogenetic protein.

An implant for articular cartilage repair includes (1) a three-dimensional body formed of cancellous bone having a demineralized section that contains bone morphogenetic proteins (BMP's) that are released by the demineralization but retained in the body, and (2) a cartilage layer formed on a surface of the demineralized section. The cartilage layer is formed by a method including the steps of (a) isolating chondrocytes from articular cartilage of a donor; (b) cultivating the isolated chondrocytes in a medium; (c) adding the cultivated chondrocytes to the demineralized section of the body, whereby the cultivated chondrocytes are stimulated by the BMP's retained in the body; and (d) incubating the cultivated chondrocytes to form a plurality of layers of chondrocytes on the demineralized section, wherein the plurality of layers of chondrocytes forms the cartilage layer.

The invention relates to a new application of sodium hydrosulfide for promoting the morphogenesis of plant roots, namely, the application is that the sodium hydrosulfide is taken as root stimulate to promote the morphogenesis of side roots and adventitious roots of the seedling of the plant and the morphogenesis of the adventitious roots of cutting branches of the plant. The sodium hydrosulfide has obvious root-promoting effect to the seedlings of the plant such as rapes, mung beans, soybeans, cucumbers and the like, the hypocotyledonary axis of the cut segment thereof and the cutting branches of the plant such as willow branches, peach branches, grapes, batatas and the like, promotes the formation and growth of the side roots and the adventitious roots of the plant, enhances the water absorbing capacity of the plant, maintains the water balance in the body of the plant, reduces membrane lipid overoxidation damage of the hypocotyledonary axis of the cut segment and the cutting branches, maintains the relative stability of membrane structure of the explant and promotes the growth and propagation of the plant. The root-promoting agent can be used for growing roots of various plant seedlings, the hypocotyledonary axis of the cut segment and the cutting branches and is applicable to the root-promoting effect of promoting and culturing the seedlings of transplanting and cutting and the like, in the agriculture, forestry and gardening.

The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein / bone morphogenetic protein (OP / BMP) family within the TGF-β superfamily of proteins.

Dysregulation of vascular function is observed in brain endothelium derived from patients affected by Alzheimer's disease. This may be manifested at the cell or organ level: e.g., abnormal capillary morphogenesis, defective angiogenesis, inappropriate cellular senescence, mitotic catastrophe, or combinations thereof. This observation can be used for diagnosis or treatment of neurodegenerative disorders and other cognitive impairments.

Production of beta-cells from stem cells from pluripotent stem cells have always been significantly lacking in at least one of the following properties: 1) functional properties related to insulin-production and glucose signaling response, 2) mature phenotype such as biochemical markers or cell structures, 3) efficiency in production of differentiated cells. Described herein is multistep differentiation protocol which substantially overcomes all of the existing limitations. Pluripotent stem cells, including induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs) can be differentiated using an embryoid body (EB) formation step, followed by B maturation via endothelial cells (EC) co-culturing and incubation with a sequential series of bone morphogenic protein (BMP)-related growth factor cocktails. The resulting cells displayed functional properties, including insulin-production and glucose signaling response, and mature phenotype of C-peptide expression.

The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.

The present invention belongs to the field of artificial organ constructing technology in medicine engineering, and is especially one kind of tissue engineering bone and its construction and application. The tissue engineering bone of the present invention includes carrier rack and seed cell attached to the carrier rack to form complex with the 3D structure and bioactivity of bone tissue. The carrier rack is modified PLGA through deacidification treatment to have great pores and high porosity, and has cell factor bone morphogenesis protein (PMP) carried; and the seed cell is marrow matrix stem cell. The tissue engineering bone of the present invention may be used in constructing functional tissue engineering bone graft for repairing large bone defect.

The invention relates to an agapanthus praecox auxin receptor protein TIR1 and a coding gene and probe thereof. The protein is: (a) a protein consisting of the amino acid sequence shown in SEQ ID No.4; or (b) a protein obtained by substituting, losing or adding one or multiple amino acids of the amino acid sequence shown in SEQ ID No.4, having agapanthus praecox auxin receptor protein activity and derived from (a). The invention also provides a nucleotide sequence for coding the protein and a probe for detecting the nucleotide sequence. According to the agapanthus praecox auxin receptor protein TIR1 and the coding gene and probe thereof provided by the invention, the agapanthus praecox auxin signal transduction pathway is regulated by the genetic engineering technology to reach an aim of controlling the growth development and organ morphogenesis, thereby providing a theoretical basis for molecular breeding and creating great application value.

This invention relates to a method for preparing mature human bone morphogenetic protein-2. The method comprise: (1) obtaining mature human bone morphogenetic protein-2 gene; (2) constructing expression vector, and transferring Escherichia coli; (3) screening to obtain positive clones, culturing and inducing to express; (4) collecting the inclusion body, and renaturing; (5) separating and purifying the expression product. The expression vector is pET series expression vector. The method has such advantages as high expression level, simple process, and low cost. The product has bioactivity, and can be used to accelerate bone tissue regeneration.

Nucleotide and amino acid sequences of cartilage-derived morphogenetic proteins (CDMP-1 and CDMP-2) from human and bovine cartilage extracts. These proteins exhibit chondrogenic activity and can be used to repair cartilage defects in a mammal.

The invention belongs to the field of genetics and breeding, in particular relates to a rice plant type related gene RL10 and application thereof. The rice gene RL10 has a sequence as shown in SEQ ID NO.1, and the rice gene RL10 codes F-box proteins and controls the polar growth of rice leaves and the morphogenesis of rice panicle traits. The gene can improve the plant types and the panicle types of the prior species, improve the yield, and has wide application prospect in the high-yield breeding of rice.

A bicellular vascular population derived from human pluripotent stem cells (hPSCs) undergoes morphogenesis and assembly in a synthetic hydrogel. It is shown that hPSCs can be induced to co-differentiate into early vascular cells (EVCs) in a clinically-relevant strategy dependent upon Notch activation. These EVCs mature into ECs and pericytes, and self-organize to form vascular networks in an engineered matrix. Upon in vivo implantation, multicellular human vascular networks are functionally perfused. Thus, a derived bicellular population is exploited for its intrinsic self-assembly capability to create functional microvasculature in a deliverable matrix.

Disclosed are compositions of benzo(c)quinolizine derivatives and methods for promoting plant and seed growth. The compounds are benzo[c]quinolizine derivatives which exert an inhibiting effect on the 5-alpha-reductase enzymes. The compounds selectively affect the growth of plants, improving morphogenesis and development of commercially useful plants while acting as herbicides to inhibit weed development.

A method of regulating flowering of a plant by applying an effective amount of a substance that affects the synthesis or amount of glutathione in cells to the plant and cultivating the plant under conditions suitable for growth.

The invention discloses a tissue culture and regenerated plant in vitro mycorrhization method for pinus massoniana, which belongs to the technical field of biotechnology and modern forestry. The method comprises the following steps of: taking a terminal bud of an aseptic seedling of the pinus massoniana as an explant, inducing to produce a large quantity of multiple shoots with strong growth first, further inducing the generation of an adventitious root, transferring a plant with the macroscopic adventitious root onto a perlite substrate under the condition of asepsis after the induction of the adventitious root is finished, and inoculating ectomycorrhizal rungi Pisolithustinctorius at the same time to realize the mycorrhization in a bottle. The mycorrhization improves the quality of a root system of the adventitious root of a tissue culture regenerated plant of the pinus massoniana, and ensures that the average lateral root number and the average root length are greatly improved. The mycorrhization also makes the state of the adventitious root greatly changed, and a fungal mantle obtained by closely arranging more than ten layers of mycelia is formed on the surface of the adventitious root. Through the method, the induction rate of the multiple shoots of the pinus massoniana reaches 95 percent, the proliferation rate reaches 430 percent, the rooting rate reaches 85 percent, and the transplantation survival rate is improved to more than 85 percent from 65 percent.